SCHEDULE: Frazier Life Sciences Amends Aura Biosciences Stake
Beneficial Ownership Report
Frazier Life Sciences funds and affiliates have filed an amended Schedule 13G, detailing their beneficial ownership in Aura Biosciences, Inc. common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. (FLSPF) beneficially owns 3,113,550 shares of Aura Biosciences, Inc. common stock, representing 5.0% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. (FLSPOF) beneficially owns 918,510 shares, representing 1.5% of the class.
- Frazier Life Sciences X, L.P. (FLS X) beneficially owns 128,520 shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. (FLS XI) beneficially owns 342,210 shares, representing 0.6% of the class.
- Frazier Life Sciences XII, L.P. (FLS XII) beneficially owns 597,210 shares, representing 1.0% of the class.
- The beneficial ownership percentages are calculated based on a total of 62,004,323 shares of Common Stock outstanding, which includes 50,268,758 shares as of May 9, 2025, and an additional 11,735,565 shares sold in a public offering.
- The filing clarifies that individual members of the investment committees for FLSPF, FLSPOF, FLS XI, and FLS XII are not attributed beneficial ownership of the securities held by these funds, correcting any prior overstatements.
- James N. Topper and Patrick J. Heron share voting and investment power over the 128,520 shares held by FLS X, each representing 0.2% beneficial ownership.
- The reporting persons also hold prefunded warrants to acquire additional shares, subject to a 9.99% beneficial ownership limitation upon exercise.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing is a standard disclosure of beneficial ownership by institutional investors in a publicly traded biotechnology company. It reflects the investment activities of Frazier Life Sciences funds in Aura Biosciences, Inc., a common occurrence in the life sciences sector where specialized funds take significant stakes in emerging companies.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership stakes and how beneficial ownership is attributed within the Frazier Life Sciences group.
- Investment Professionals: Offers updated data on a key investor's position in Aura Biosciences, which can influence market perception and trading strategies.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-05-09 | Date of Issuer's Common Stock outstanding count (50,268,758 shares) as reported in Quarterly Report on Form 10-Q. |
| 2025-05-15 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-05-16 | Date Issuer's Prospectus Supplement for public offering was filed with the SEC, detailing the sale of 11,735,565 shares. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Aura Biosciences, Frazier Life Sciences, Beneficial Ownership, Schedule 13G, Common Stock, Investment Fund, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.